Ligand files XOMA Royalty financials post-merger; acquired firm lost $41.2M in H1 2026

LIGAND PHARMACEUTICALS INC

Merger with XOMA Royalty closed; deal agreement dated April 27, 2026, amended May 16, 2026.
XOMA Royalty H1 2026 (unaudited): net loss $41.2M, total assets $244.3M, accumulated deficit $1.26B.
H1 2026 charges: $23.6M impairment, $19.7M credit losses on purchased receivables; income/revenues $29.3M.
Cash, equivalents, and restricted cash $150.6M at June 30, 2026; liquidity assessed sufficient for at least one year.
Pro forma combined financial statements filed for periods ended June 30, 2026 and December 31, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.